Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 12/20 | 0.66 |
| ▸ | MMP13 | P45452 | 11/20 | 0.66 |
| ▸ | MMP2 | P08253 | 10/20 | 0.66 |
| ▸ | MMP9 | P14780 | 9/20 | 0.66 |
| ▸ | MMP3 | P08254 | 7/20 | 0.66 |
| ▸ | ADAM17 | P78536 | 8/20 | 0.66 |
| ▸ | MMP14 | P50281 | 7/20 | 0.61 |
| ▸ | MMP8 | P22894 | 4/20 | 0.61 |
| ▸ | MMP10 | P09238 | 3/20 | 0.61 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.61 |
| ▸ | MMP7 | P09237 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7310372 | 0.90 | MMP13 (0.76) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL7681442 | 0.89 | MMP1 (0.55) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL7306093 | 0.86 | MMP1 (0.81) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL6785491 | 0.82 | OPRM1 (0.50) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL6622931 | 0.81 | MMP13 (0.50) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL6791098 | 0.81 | ADAM17 (0.61) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL6789202 | 0.80 | MMP13 (1.00) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL6795687 | 0.80 | MMP1 (1.00) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL5919502 | 0.80 | MMP13 (0.80) | MMP1MMP13MMP2MMP9MMP3 | |
| SCHEMBL6753832 | 0.79 | ADAM17 (1.00) | MMP1MMP13MMP2MMP9ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040097487-A1 | Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds | G.D. SEARLE & CO. | 2004-05-20 | — | — | US | disclosed |
| US-6638952-B1 | Matrix metalloprotease inhibitors | PHARMACIA CORPORATION | 2003-10-28 | — | — | US | disclosed |
| EP-0983257-A4 | AROMATIC SULFONYL ALPHA-CYCLOAMINO HYDROXAMIC ACID COMPOUNDS | MONSANTO CO (US) | 2001-05-02 | — | — | EP | disclosed |
| EP-0983257-A1 | AROMATIC SULFONYL ALPHA-CYCLOAMINO HYDROXAMIC ACID COMPOUNDS | Monsanto Company (US) | 2000-03-08 | — | — | EP | disclosed |
| WO-1998039315-A1 | AROMATIC SULFONYL ALPHA-CYCLOAMINO HYDROXAMIC ACID COMPOUNDS | MONSANTO COMPANY (US) | 1998-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097487-A1 | Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds | MMP1, MMP2, MMP10 | MMP1 1/4885MMP13 10/4885MMP2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.